Biodexa Completes Treatment in Pediatric Glioma Treatment Study; Shares Up 90%
Biodexa Ltd (Nasdaq: BDRX) has completed enrolment and treatment in its Phase 1 study of MTX110 in the treatment of children with newly diagnosed diffuse midline gliomas (DMGs). Biodexa expects to release full study results in Q1 2024.
The company’s share price rose more than 90% to $8.12 following the news.
Highlights
The investigator-sponsored study has enrolled and treated nine patients aged between 4 and 17 years.
No dose limiting toxicities related to the study drug have been reported in the study.
Full study results are expected to be released in Q1 2024.
MTX110 is a liquid formulation of the histone deacetylase (HDAC) inhibitor, panobinostat. Biodexa’s proprietary formulation is delivered via convection-enhanced delivery (CED) at potentially therapeutic doses directly to the site of the tumor, by-passing the blood-brain barrier and avoiding systemic toxicity.
DMG represents a very high unmet medical need with a lack of effective treatments and poor survival at an average of 9-11 months.
About Biodexa
Biodexa Pharmaceuticals PLC (listed on NASDAQ: BDRX) is a clinical stage biopharmaceutical company developing a pipeline of products aimed at primary and metastatic cancers of the brain. The Company’s lead candidate, MTX110, is being studied in aggressive rare/orphan brain cancer indications including recurrent glioblastoma and diffuse midline glioma.
Biodexa is supported by three proprietary drug delivery technologies focused on improving the bio-delivery and bio-distribution of medicines. Biodexa’s headquarters and R&D facility is in Cardiff, UK. For more information visit https://biodexapharma.com.
